Featured Research

from universities, journals, and other organizations

Drug Offers New Hope For Victims Of Cardiac Arrest

Date:
September 20, 1999
Source:
University Of Washington
Summary:
A clinical trial performed by University of Washington researchers, reported in the Sept. 16 issue of the New England Journal of Medicine, shows that an intravenous anti-arrhythmia medication, amiodarone, can save the lives of many patients who do not respond to defibrillation.

The threat of imminent death awaits the 250,000 persons who suffer a cardiac arrest outside the hospital each year, especially those for whom defibrillation fails to shock the heart back to normal beating.

A clinical trial performed by University of Washington researchers, reported in the Sept. 16 issue of the New England Journal of Medicine, shows that an intravenous anti-arrhythmia medication, amiodarone, can save the lives of many patients who do not respond to defibrillation.

Dr. Peter Kudenchuk, associate professor of medicine and director of arrhythmia services at University of Washington Medical Center in Seattle, and colleagues performed the study, called ARREST (Amiodarone in the Out-of-Hospital Resuscitation of Refractory Sustained Ventricular Tacharrhythmias). The study was performed in conjunction with Medic One, Seattle/King County's highly regarded emergency response service based at Harborview Medical Center.

They found that resuscitation to a stable heart rhythm was improved by nearly 30 percent in people treated with intravenous amiodarone by emergency medical personnel at the scene of their collapse, compared to those who received other standard treatments for cardiac arrest.

This benefit was seen even when amiodarone was given late in the course of resuscitation, and was especially evident in women compared to men.

Kudenchuk noted that the clinical trial is the first of its kind to compare the effectiveness of an anti-arrhythmia medication with all standard treatments in victims of out-of-hospital cardiac arrest.

The drug was administered to 504 people in Seattle and surrounding King County, Wash., who suffered cardiac arrest due to a dangerous heart rhythm (ventricular fibrillation) and were treated at the scene by Medic One. Patients ranged in age from 20 to 94 years. The majority were men and the majority went into cardiac arrest at home.

"For every 10 persons treated with amiodarone for shock-resistant cardiac arrest, one additional person was resuscitated and admitted alive to the hospital," said Kudenchuk.

He noted that the main treatment endpoint for the ARREST trial was being successfully resuscitated and admitted to the hospital. The trial was not designed to evaluate the effect of amiodarone treatment on outcome after hospitalization. Although a small improvement in survival to hospital discharge with full recovery of brain function was observed in persons treated with amiodarone, the investigators did not feel that this difference was conclusive.

"Stopping the cardiac arrest and successfully getting patients to the hospital is a big step, but it's only the first hurdle," said Kudenchuk. "The next step is to determine whether drugs like amiodarone can improve long-term survival after cardiac arrest. "

Amiodarone is marketed as Cordarone IV by Wyeth-Ayerst Laboratories. The Medic One Foundation provided approximately two-thirds of the funding for the study and Wyeth-Ayerst, approximately one-third.


Story Source:

The above story is based on materials provided by University Of Washington. Note: Materials may be edited for content and length.


Cite This Page:

University Of Washington. "Drug Offers New Hope For Victims Of Cardiac Arrest." ScienceDaily. ScienceDaily, 20 September 1999. <www.sciencedaily.com/releases/1999/09/990920072033.htm>.
University Of Washington. (1999, September 20). Drug Offers New Hope For Victims Of Cardiac Arrest. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1999/09/990920072033.htm
University Of Washington. "Drug Offers New Hope For Victims Of Cardiac Arrest." ScienceDaily. www.sciencedaily.com/releases/1999/09/990920072033.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins